{
    "id": 32829,
    "fullName": "SLC3A2 - NRG1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "SLC3A2-NRG1 results from the fusion of SLC3A2 and NRG1, which leads to activation of the Erbb2-Erbb3 heterocomplex as demonstrated by increased phosphorylation of Erbb2 and Erbb3, and results in increased cell proliferation and migration in culture and increased tumor volume in mouse models (PMID: 27626312). SLC3A2-NRG1 fusions have been identified in non-small cell lung cancer (PMID: 29959202).",
            "references": [
                {
                    "id": 18262,
                    "pubMedId": 27626312,
                    "title": "Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27626312"
                },
                {
                    "id": 18238,
                    "pubMedId": 29959202,
                    "title": "Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29959202"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6520,
        "geneSymbol": "SLC3A2",
        "terms": [
            "SLC3A2",
            "4F2",
            "4F2HC",
            "4T2HC",
            "CD98",
            "CD98HC",
            "MDU1",
            "NACAE"
        ]
    },
    "variant": "SLC3A2 - NRG1",
    "createDate": "03/18/2020",
    "updateDate": "04/02/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 3084,
                "geneSymbol": "NRG1",
                "terms": [
                    "NRG1",
                    "ARIA",
                    "GGF",
                    "GGF2",
                    "HGL",
                    "HRG",
                    "HRG1",
                    "HRGA",
                    "MST131",
                    "MSTP131",
                    "NDF",
                    "NRG1-IT2",
                    "SMDF"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 21011,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing SLC3A2-NRG1 demonstrated reduced growth in culture and decreased tumor growth in cell line xenograft models when treated with Gilotrif (afatinib) (PMID: 29959202).",
            "molecularProfile": {
                "id": 35493,
                "profileName": "SLC3A2 - NRG1"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18238,
                    "pubMedId": 29959202,
                    "title": "Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29959202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21027,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell line xenograft models expressing SLC3A2-NRG1 demonstrated a greater reduction in tumor growth when treated with a combination of Gilotrif (afatinib) and Taxol (paclitaxel) compared to Gilotrif (afatinib) alone (PMID: 29959202).",
            "molecularProfile": {
                "id": 35493,
                "profileName": "SLC3A2 - NRG1"
            },
            "therapy": {
                "id": 2441,
                "therapyName": "Afatinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18238,
                    "pubMedId": 29959202,
                    "title": "Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29959202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21012,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing SLC3A2-NRG1 demonstrated reduced growth in culture and decreased tumor growth in cell line xenograft models when treated with Perjeta (pertuzumab) (PMID: 29959202).",
            "molecularProfile": {
                "id": 35493,
                "profileName": "SLC3A2 - NRG1"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18238,
                    "pubMedId": 29959202,
                    "title": "Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29959202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21030,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell line xenograft models expressing SLC3A2-NRG1 demonstrated a greater reduction in tumor growth when treated with a combination of Lumretuzumab and Taxol (paclitaxel) compared to Lumretuzumab alone (PMID: 29959202).",
            "molecularProfile": {
                "id": 35493,
                "profileName": "SLC3A2 - NRG1"
            },
            "therapy": {
                "id": 9536,
                "therapyName": "Lumretuzumab + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18238,
                    "pubMedId": 29959202,
                    "title": "Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29959202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21013,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing SLC3A2-NRG1 demonstrated reduced growth in culture and decreased tumor growth in cell line xenograft models when treated with Lumretuzumab (PMID: 29959202).",
            "molecularProfile": {
                "id": 35493,
                "profileName": "SLC3A2 - NRG1"
            },
            "therapy": {
                "id": 3546,
                "therapyName": "Lumretuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18238,
                    "pubMedId": 29959202,
                    "title": "Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29959202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21029,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cell line xenograft models expressing SLC3A2-NRG1 demonstrated a greater reduction in tumor growth when treated with a combination of Perjeta (pertuzumab) and Taxol (paclitaxel) compared to Perjeta (pertuzumab) alone (PMID: 29959202).",
            "molecularProfile": {
                "id": 35493,
                "profileName": "SLC3A2 - NRG1"
            },
            "therapy": {
                "id": 9535,
                "therapyName": "Paclitaxel + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18238,
                    "pubMedId": 29959202,
                    "title": "Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29959202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21025,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing SLC3A2-NRG1 demonstrated reduced growth in culture and decreased tumor growth in cell line xenograft models when treated with a combination of Lumretuzumab and Perjeta (pertuzumab) (PMID: 29959202).",
            "molecularProfile": {
                "id": 35493,
                "profileName": "SLC3A2 - NRG1"
            },
            "therapy": {
                "id": 9534,
                "therapyName": "Lumretuzumab + Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18238,
                    "pubMedId": 29959202,
                    "title": "Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29959202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35493,
            "profileName": "SLC3A2 - NRG1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}